Demyelinating disease and psoriasis: interferon versus dimethyl fumarate

J Neurol Sci. 2014 Aug 15;343(1-2):230-1. doi: 10.1016/j.jns.2014.05.031. Epub 2014 May 27.

Authors

Lynn G Howard¹, Roberto Bomprezzi²

Affiliations

¹ MaineGeneral Neurology, United States; MaineGeneral Medical Center, United States.
² MaineGeneral Neurology, United States; MaineGeneral Medical Center, United States. Electronic address: rbomprez@gmail.com.

PMID: 24906711
DOI: 10.1016/j.jns.2014.05.031

No abstract available

Keywords: Demyelinating disease; Dimethyl fumarate; Interferon; Psoriasis.

Publication types

Case Reports
Letter

MeSH terms

Adult
Antiviral Agents / therapeutic use*
Demyelinating Diseases / complications
Demyelinating Diseases / drug therapy*
Dimethyl Fumarate
Fumarates / therapeutic use*
Humans
Immunosuppressive Agents / therapeutic use*
Interferons / therapeutic use*
Magnetic Resonance Imaging
Male
Psoriasis / drug therapy*
Psoriasis / etiology

Substances

Antiviral Agents
Fumarates
Immunosuppressive Agents
Interferons
Dimethyl Fumarate